The stock of Auxilium Pharmaceuticals (AUXL), a specialty biopharmaceutical company, corrected almost 45% in the last 10 months from its 52-week high at $25.54 in the absence of any meaningful catalysts. Since May the stock gradually started to build a positive momentum again after creating a 52-week low at $13.87. Currently Auxilium is consolidating just below $18, and I feel slowly but steadily the stock is heading towards $25 again. In this investment thesis I will explain why the stock is worth buying at the current level with ~75% upside in the next one year.
Auxilium, together with its subsidiaries, develops and markets specialty pharmaceutical products worldwide. Auxilium's lead two products are Testim and Xiaflex. Testim...
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: